Statement of Changes in Beneficial Ownership (4)
22 June 2018 - 6:35AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Almstead Neil Gregory
|
2. Issuer Name
and
Ticker or Trading Symbol
PTC THERAPEUTICS, INC.
[
PTCT
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
_____ 10% Owner
__
X
__ Officer (give title below)
_____ Other (specify below)
EVP Research Pharma Ops & Tech
|
(Last)
(First)
(Middle)
C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
6/19/2018
|
(Street)
SOUTH PLAINFIELD, NJ 07080
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock
|
6/19/2018
|
|
M
(1)
|
|
20000
|
A
|
$10.85
|
37154
|
D
|
|
Common Stock
|
6/19/2018
|
|
S
(1)
|
|
8000
|
D
|
$48.09
(2)
|
29154
|
D
|
|
Common Stock
|
6/19/2018
|
|
S
(1)
|
|
12000
|
D
|
$48.46
(3)
|
17154
|
D
|
|
Common Stock
|
|
|
|
|
|
|
|
5125
|
I
|
By spouse
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Stock Option (Right To Buy)
|
$10.85
|
6/19/2018
|
|
M
(1)
|
|
|
20000
|
(4)
|
5/15/2023
|
Common Stock
|
20000.0
|
$10.85
|
46898
|
D
|
|
Stock Option (Right To Buy)
|
$451.2
|
|
|
|
|
|
|
(4)
|
5/15/2019
|
Common Stock
|
200.0
|
|
200
|
D
|
|
Stock Option (Right To Buy)
|
$1149.6
|
|
|
|
|
|
|
(4)
|
2/2/2020
|
Common Stock
|
200.0
|
|
200
|
D
|
|
Stock Option (Right To Buy)
|
$490.8
|
|
|
|
|
|
|
(4)
|
4/27/2021
|
Common Stock
|
216.0
|
|
216
|
D
|
|
Stock Option (Right To Buy)
|
$218.4
|
|
|
|
|
|
|
(4)
|
1/10/2022
|
Common Stock
|
166.0
|
|
166
|
D
|
|
Stock Option (Right To Buy)
|
$10.85
|
|
|
|
|
|
|
(4)
|
5/15/2023
|
Common Stock
|
3102.0
|
|
3102
|
D
|
|
Stock Option (Right To Buy)
|
$27.05
|
|
|
|
|
|
|
(4)
|
1/27/2024
|
Common Stock
|
40000.0
|
|
40000
|
D
|
|
Stock Option (Right To Buy)
|
$51.0
|
|
|
|
|
|
|
(5)
|
1/1/2025
|
Common Stock
|
69550.0
|
|
69550
|
D
|
|
Stock Option (Right To Buy)
|
$30.86
|
|
|
|
|
|
|
(6)
|
1/3/2026
|
Common Stock
|
55000.0
|
|
55000
|
D
|
|
Stock Option (Right To Buy)
|
$11.23
|
|
|
|
|
|
|
(7)
|
1/2/2027
|
Common Stock
|
35000.0
|
|
35000
|
D
|
|
Stock Option (Right To Buy)
|
$18.01
|
|
|
|
|
|
|
(8)
|
1/2/2028
|
Common Stock
|
70000.0
|
|
70000
|
D
|
|
Stock Option (Right To Buy)
|
$508.8
|
|
|
|
|
|
|
(4)
|
10/7/2019
|
Common Stock
|
12.0
|
|
12
|
I
|
By spouse
|
Stock Option (Right To Buy)
|
$1149.6
|
|
|
|
|
|
|
(4)
|
2/2/2020
|
Common Stock
|
1.0
|
|
1
|
I
|
By spouse
|
Stock Option (Right To Buy)
|
$490.8
|
|
|
|
|
|
|
(4)
|
4/27/2021
|
Common Stock
|
7.0
|
|
7
|
I
|
By spouse
|
Stock Option (Right To Buy)
|
$218.4
|
|
|
|
|
|
|
(4)
|
1/10/2022
|
Common Stock
|
7.0
|
|
7
|
I
|
By spouse
|
Stock Option (Right To Buy)
|
$27.05
|
|
|
|
|
|
|
(4)
|
1/27/2024
|
Common Stock
|
1300.0
|
|
1300
|
I
|
By spouse
|
Stock Option (Right To Buy)
|
$51.0
|
|
|
|
|
|
|
(5)
|
1/1/2025
|
Common Stock
|
2060.0
|
|
2060
|
I
|
By spouse
|
Explanation of Responses:
|
(1)
|
The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan.
|
(2)
|
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $47.58 to $48.37 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
|
(3)
|
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $48.38 to $48.81 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
|
(4)
|
Currently exercisable.
|
(5)
|
This option was granted on January 2, 2015, and vests over four years, with 25% of the shares underlying the option vesting on January 1, 2016, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 1, 2016.
|
(6)
|
This option was granted on January 4, 2016, and vests over four years, with 25% of the shares underlying the option vesting on January 4, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 4, 2017.
|
(7)
|
This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.
|
(8)
|
This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Almstead Neil Gregory
C/O PTC THERAPEUTICS, INC.
100 CORPORATE COURT
SOUTH PLAINFIELD, NJ 07080
|
|
|
EVP Research Pharma Ops & Tech
|
|
Signatures
|
/s/ Avraham S. Adler, attorney-in-fact
|
|
6/21/2018
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
PTC Therapeutics (NASDAQ:PTCT)
Historical Stock Chart
From Apr 2024 to May 2024
PTC Therapeutics (NASDAQ:PTCT)
Historical Stock Chart
From May 2023 to May 2024